Sailon Pharmaceuticals: Subsidiary Granted Approval for Listing Application of Rabeprazole Sodium Chemical Raw Material

Sailon Pharmaceuticals announced that its wholly-owned subsidiary, Hunan Sailon Pharmaceuticals, recently obtained the approval and issuance of the Lansoprazole Sodium Chemical Raw Material Drug Market Approval Notice by the National Medical Products Administration. The notice number is 2025YS01099, valid until December 10, 2030. Lansoprazole sodium injection is used to treat bleeding gastric ulcers or duodenal ulcers when oral therapy is not applicable. This approval will enrich the company's portfolio of raw materials, but there are uncertainties in production and sales. The company will disclose information as the situation develops.